Internal Reference Number: FOI_6770
Date Request Received: 07/09/2022 00:00:00
Date Request Replied To: 20/09/2022 00:00:00
This response was sent via: By Email
Request Summary: Cancer tx and clinical trials
Request Category: Private Individuals
| Question Number 1: Does your trust provide SACT (systemic anti-cancer therapy) treatments for the following conditions? • Cervical cancer • Endometrial cancer In case you do not provide SACT treatments for either of the above conditions, which other trust do you refer patients to for these treatments? | |
| Answer To Question 1: Yes | |
| Question Number 2: How many patients were treated for cervical cancer in the past 6 months with the following treatments: • Paclitaxel in combination with Platinum and/or Bevacizumab • Pembrolizumab in combination with Platinum and/or Bevacizumab • Platinum standalone or in combination with Bevacizumab • Toptecan in combination with Platinum and/or Bevacizumab • Any other SACT | |
| Answer To Question 2: • Paclitaxel in combination with Platinum and/or Bevacizumab <5 • Pembrolizumab in combination with Platinum and/or Bevacizumab 0 • Platinum standalone or in combination with Bevacizumab 0 • Toptecan in combination with Platinum and/or Bevacizumab 0 • Any other SACT 0 | |
| Question Number 3: How many patients were treated for endometrial cancer in the past 6 months with the following treatments: • Dostarlimab • Hormone therapy (Progesterone or Letrozole) • Pembrolizumab in combination with Lenvatinib • Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) • Any other SACT | |
| Answer To Question 3: • Dostarlimab 0 • Hormone therapy (Progesterone or Letrozole) 0 • Pembrolizumab in combination with Lenvatinib 0 • Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) <5 • Any other SACT 0 | |
| Question Number 4: How many endometrial cancer patients received the following therapies as 1st Line treatment in the past 6 months: • Hormone therapy (Progesterone or Letrozole) • Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) • Any other SACT | |
| Answer To Question 4: • Hormone therapy (Progesterone or Letrozole) 0 • Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) <5 | |
| Question Number 5: Does your trust participate in any clinical trials for the treatment of cervical cancer? If so, can you please provide the name of each trial and the number of patients taking part. | |
| Answer To Question 5: no | |
| Question Number 6: Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part. | |
| Answer To Question 6: no | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of ¾¨Ó㴫ý Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
